Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-26

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis

NCT05273138

Systemic Sclerosis

RECRUITING

Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

NCT04265144

Scleroderma Systemic Sclerosis

RECRUITING NA

Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis

NCT07015060

Scleroderma (Limited and Diffuse)

NOT_YET_RECRUITING NA

Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis

NCT02636127

Scleroderma, Systemic

COMPLETED NA

BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA

NCT03629002

Systemic Scleroderma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scleroderma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

scleroderma

People with systemic scleroderma

Skin samples

Intervention Type PROCEDURE

* Scleroderma group: skin biopsy for scleroderma patients
* Control group: recovery of resected tissue from patients undergoing plastic, reconstructive and aesthetic surgery.

Analysis of fibroblasts

Intervention Type OTHER

Analysis of samples by RNA sequencing

Control

People undergoing plastic, cosmetic and reconstructive surgery

Skin samples

Intervention Type PROCEDURE

* Scleroderma group: skin biopsy for scleroderma patients
* Control group: recovery of resected tissue from patients undergoing plastic, reconstructive and aesthetic surgery.

Analysis of fibroblasts

Intervention Type OTHER

Analysis of samples by RNA sequencing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin samples

* Scleroderma group: skin biopsy for scleroderma patients
* Control group: recovery of resected tissue from patients undergoing plastic, reconstructive and aesthetic surgery.

Intervention Type PROCEDURE

Analysis of fibroblasts

Analysis of samples by RNA sequencing

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

FOR PATIENTS WITH SCLERODERMA :

* Person who has given written consent
* Person with systemic scleroderma

FOR CONTROL PARTICIPANTS :

* Person who has given written consent
* Person undergoing plastic, cosmetic and reconstructive surgery

Exclusion Criteria

FOR PATIENTS WITH SCLERODERMA :

* Person not affiliated to or not benefiting from a social security scheme
* Person subject to a legal protection measure (curatorship, guardianship)
* Person subject to a legal protection measure
* An adult who is incapable or unable to give consent
* Minors

FOR CONTROLLED PARTICIPANTS :

* Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases
* Person not affiliated to or not benefiting from a social security scheme
* Person under legal protection (curatorship, guardianship)
* Person subject to a legal protection measure
* An adult who is incapable or unable to give consent
* Minors

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes